On the morning of April 25, 2024, Ben Tre Pharmaceutical Joint Stock Company (Bepharco) convened its Annual General Meeting of Shareholders (AGM) for the financial year 2023.

During the session, the AGM deliberated and approved: the report on the company's activities in 2023 and the business plan for 2024; the review of the Board of Directors' activities in 2023; the audited financial statement for 2023, profit allocation for 2023; profit distribution plan for 2024; and other pertinent matters within the purview of the AGM.

Despite encountering various challenges and market fluctuations in 2023, Bepharco demonstrated resilience by meeting its predetermined objectives. Notably, the company attained a revenue of 816 billion VND and strategically invested in acquiring a state-of-the-art facility specializing in manufacturing health food products compliant with GMP-WHO standards, namely the Ypharco Healthcare factory.

During the AGM, the election for the new term's Board of Directors was conducted, resulting in the appointment of Mr. Nguyen Khac Hanh, Mr. Pham Thu Trieu, Mr. Hoang Xuan An, Mr. Tran Nguyen Gia Bao, and Mr. Nguyen Thanh Tung as elected members.

In 2024, with a target gross revenue of 1,100 billion VND, all Bepharco employees are poised to embrace a fresh perspective and direction, dedicated to contributing their utmost efforts. Upholding sustainable development principles and generating tangible value for the community and society remain paramount objectives for Bepharco. This journey is underscored by sincere appreciation for the unwavering trust and support extended by shareholders, partners, and esteemed customers.